|1.||Ye, Wencai: 3 articles (10/2015 - 01/2007)|
|2.||Zheng, Yuanting: 2 articles (04/2010 - 01/2007)|
|3.||Yan, Bei: 2 articles (04/2010 - 01/2007)|
|4.||Wang, Guangji: 2 articles (04/2010 - 01/2007)|
|5.||Wu, Xiaolan: 2 articles (04/2010 - 01/2007)|
|6.||Ye, Wen-Cai: 2 articles (09/2004 - 11/2002)|
|7.||Zhu, Peiqing: 1 article (10/2015)|
|8.||Yao, Hequan: 1 article (10/2015)|
|9.||Wu, Xiaoming: 1 article (10/2015)|
|10.||Zhang, Hengyuan: 1 article (10/2015)|
10/01/2015 - "Most of the newly synthesized compounds exhibited more potent antiproliferative activity than patent compound 23-hydroxybetulinic acid, especially 13e and 14a were about four- to sevenfold more potent against all tested cancer cell lines than 23-hydroxybetulinic acid. "
11/22/2002 - "Our data suggest that 23-hydroxybetulinic acid may be a potential cytotoxic agent for treatment of cancer."
04/21/2010 - "23-Hydroxybetulinic acid showed a synergistic cytotoxic effect on multiple cancer cell lines by combined use with doxorubicin. "
04/21/2010 - "The effect of combination treatment with 23-hydroxybetulinic acid and doxorubicin was evaluated with a quantitative combination index method based on the median-effect analysis in various cancer cell lines. "
09/13/2004 - "Of the five compounds tested, 3-oxo-23-hydroxybetulinic acid was the most cytotoxic on murine melanoma B16 cells (IC50=22.5 microg/ml), followed by 23-hydroxybetulinic acid and betulinic acid (IC50=32 and 76 microg/ml, respectively), with lupeol and betulin exhibiting the weakest cytotoxicity (IC50> or =100 microg/ml). "
|2.||Telomerase (Telomerase Reverse Transcriptase)